Generic-Drug Makers Get Top Court Review on Patient Suits

The U.S. Supreme Court will take up calls by the generic-drug industry for stricter limits on lawsuits by patients, agreeing to review a $21 million award to a woman who suffered debilitating injuries after taking a painkiller.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.